130 related articles for article (PubMed ID: 23065527)
1. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
[TBL] [Abstract][Full Text] [Related]
2. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J; Hamadani M; Wu J; Al Malki MM; Martens MJ; Runaas L; Elmariah H; Rezvani AR; Gooptu M; Larkin KT; Shaffer BC; El Jurdi N; Loren AW; Solh M; Hall AC; Alousi AM; Jamy OH; Perales MA; Yao JM; Applegate K; Bhatt AS; Kean LS; Efebera YA; Reshef R; Clark W; DiFronzo NL; Leifer E; Horowitz MM; Jones RJ; Holtan SG;
N Engl J Med; 2023 Jun; 388(25):2338-2348. PubMed ID: 37342922
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
4. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
Cutler C; Li S; Ho VT; Koreth J; Alyea E; Soiffer RJ; Antin JH
Blood; 2007 Apr; 109(7):3108-14. PubMed ID: 17138818
[TBL] [Abstract][Full Text] [Related]
5. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
[TBL] [Abstract][Full Text] [Related]
6. Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies.
Amanam I; Otoukesh S; Al Malki MM; Salhotra A
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):164-170. PubMed ID: 38066845
[TBL] [Abstract][Full Text] [Related]
7. Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.
McDermott CL; Sandmaier BM; Storer B; Li H; Mager DE; Boeckh MJ; Bemer MJ; Knutson J; McCune JS
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1159-66. PubMed ID: 23660171
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
Cutler C; Stevenson K; Kim HT; Richardson P; Ho VT; Linden E; Revta C; Ebert R; Warren D; Choi S; Koreth J; Armand P; Alyea E; Carter S; Horowitz M; Antin JH; Soiffer R
Blood; 2008 Dec; 112(12):4425-31. PubMed ID: 18776081
[TBL] [Abstract][Full Text] [Related]
9. [Clinical analysis of sirolimus as an alternative GVHD prophylaxis for patients with kidney injury undergoing allo-HSCT].
Sun W; Ma R; He Y; Bai L; Chen YY; Chen Y; Zhang YY; Wang JZ; Chen H; Zhang XH; Xu LP; Wang Y; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2023 Dec; 62(12):1444-1450. PubMed ID: 38044071
[No Abstract] [Full Text] [Related]
10. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease.
Magenau J; Jaglowski S; Uberti J; Farag SS; Riwes MM; Pawarode A; Anand S; Ghosh M; Maciejewski J; Braun T; Devenport M; Lu S; Banerjee B; DaSilva C; Devine S; Zhang MJ; Burns LJ; Liu Y; Zheng P; Reddy P
Blood; 2024 Jan; 143(1):21-31. PubMed ID: 37647633
[TBL] [Abstract][Full Text] [Related]
11. Reduced Incidence of Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Calcineurin-Free Graft-versus-Host Disease Prophylaxis.
Balaguer-Roselló A; Gil-Perotín S; Montoro J; Bataller L; Lamas B; Villalba M; Facal A; Guerreiro M; Chorão P; Bataller A; Granados P; Gómez I; Solves P; Louro A; de la Rubia J; Sanz MÁ; Sanz J
Transplant Cell Ther; 2023 Oct; 29(10):610.e1-610.e12. PubMed ID: 37451486
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.
Storb R; Gyurkocza B; Storer BE; Maloney DG; Sorror ML; Mielcarek M; Martin PJ; Sandmaier BM
Biol Blood Marrow Transplant; 2013 May; 19(5):792-8. PubMed ID: 23416851
[TBL] [Abstract][Full Text] [Related]
13. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.
Ziakas PD; Zervou FN; Zacharioudakis IM; Mylonakis E
PLoS One; 2014; 9(12):e114735. PubMed ID: 25485632
[TBL] [Abstract][Full Text] [Related]
15. High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention.
Holtzman NG; Curtis LM; Salit RB; Shaffer BC; Pirsl F; Ostojic A; Steinberg SM; Schulz E; Wilder JS; Hughes TE; Rose J; Memon S; Korngold R; Gea-Banacloche J; Fowler DH; Hakim FT; Gress RE; Bishop MR; Pavletic SZ
Blood Adv; 2024 Apr; ():. PubMed ID: 38669315
[TBL] [Abstract][Full Text] [Related]
16. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
[TBL] [Abstract][Full Text] [Related]
17. Effects of Immunosuppressive Medications on Mitochondrial Function.
Nash A; Samoylova M; Leuthner T; Zhu M; Lin L; Meyer JN; Brennan TV
J Surg Res; 2020 May; 249():50-57. PubMed ID: 31918330
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of immunosuppressive regimens used as maintenance therapy in kidney transplantation: The CESIT study.
Bellini A; Finocchietti M; Rosa AC; Nordio M; Ferroni E; Massari M; Spila Alegiani S; Masiero L; Bedeschi G; Cardillo M; Lucenteforte E; Piccolo G; Leoni O; Pierobon S; Ledda S; Garau D; Davoli M; Addis A; Belleudi V;
PLoS One; 2024; 19(1):e0295205. PubMed ID: 38165971
[TBL] [Abstract][Full Text] [Related]
19. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
Alyea EP; DeAngelo DJ; Moldrem J; Pagel JM; Przepiorka D; Sadelin M; Young JW; Giralt S; Bishop M; Riddell S
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1037-69. PubMed ID: 20580849
[TBL] [Abstract][Full Text] [Related]
20. Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies.
Raghunandan S; Qayed M; Watkins BK; Graiser M; Gorfinkel L; Westbrook A; Gillespie S; Bratrude B; Petrovic A; Suessmuth Y; Horan J; Kean LS; Langston AA
Bone Marrow Transplant; 2023 Nov; 58(11):1264-1266. PubMed ID: 37580397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
